Opinion|Videos|April 11, 2025
Personalizing Treatment in Alopecia Areata
Author(s)Arash Mostaghimi, MD, MPH, Brett King, MD, PhD
A panelist discusses how determining whether a Janus kinase (JAK) inhibitor is the appropriate treatment for alopecia areata patients, which involves carefully evaluating disease severity, duration, and extent of hair loss, considering previous treatment failures, assessing patient comorbidities and risk factors, reviewing comprehensive laboratory results, discussing potential benefits vs risks of JAK therapy, and establishing realistic expectations about treatment timeline and potential adverse effects.
Advertisement
Episodes in this series
How do you decide whether a JAK inhibitor is an appropriate treatment option for a patient?
Advertisement
Related to this article
Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.
In mice, liraglutide reduced steatosis through PPARα without needing iNKT cells, pointing to a possible GLP-1 RA plus PPARα combination.
In pooled, propensity-matched data, SC infliximab achieved week 54 endoscopic response in 65.7% of patients with ileal Crohn’s disease vs 27.1% with IV.
In ADtouch, lebrikizumab improved clearance, itch, and pain in hand and foot atopic dermatitis. Shawn Kwatra, MD, discusses what the data mean.
Phase 3 SHINE-2 data show 41.3% of children and adolescents with UC reached clinical remission after 12 weeks of mirikizumab induction.
A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.
Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.
In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.
Advertisement
Advertisement
Trending on HCPLive
1
Tezepelumab Meets Co-Primary End Points in Phase 3 CROSSING Trial in EoE
2
Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE
3
Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years
4
EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know
5